For example, glioma, hepatocellular carcinoma, head and neck squamous cell carcinoma, myeloid leukemia, colorectal, pancreatic, gastric, oral, breast, and non-small-cell lung malignancies all have changed expression levels of PER1, PER2, and PER3. This evidence concerns the gene PER2 and central nervous system cancer.